IP Library Granted Patent US 11,530,438
Granted Patent B2
US 11,530,438 · App. 16/483,383 · Granted Dec 20, 2022

Highly specific circular proximity ligation assay

Inventors: Henrik H. J. Persson (Palo Alto, CA); Roxana Jalili (Palo Alto, CA); Joseph L. Horecka (Stanford, CA); Ronald W. Davis (Palo Alto, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
C12Q1/6816C12Q1/6851C12Q2521/501C12Q2523/307C12Q2531/125C12Q2537/162C12Y605/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,530,438
App. No.
16/483,383
Granted
Dec 20, 2022
Kind
B2
Abstract

Provided herein is a circular proximity ligation assay in which proximity-probes are employed as bridges to connect two free oligonucleotides via a dual ligation event, resulting in the formation of a circle. The circles are then quantified by, e.g., qPCR. The addition of an extra oligonucleotide is believed to enhance specificity by decreasing the probability of random background ligation events. In addition, circle formation may have selective advantages, as uncircularized DNA can be removed by a simple exonuclease treatment and it has streamlined the workflow by eliminating preamplification prior to qPCR.

Claims (28)

1. A method for sample analysis comprising:

(a) incubating a sample of blood plasma or serum comprising a target analyte that is at a concentration of less than 100 nM with:

(i) a first conjugate comprising a binding agent and a first splint oligonucleotide, and

(ii) a second conjugate comprising a binding agent and a second splint oligonucleotide,

wherein the first and second conjugates are a polyclonal antibody that has been affinity purified, split into a first portion and a second portion, and then conjugated to the first and second splint oligonucleotides,

under conditions suitable for binding of the binding agents of the first and second conjugates to the target analyte, to produce a product;

(b) incubating at least some of the product of step (a) with:

(i) a set of probes that produces a ligatable circle only when the probes are hybridized to the first and second splint oligonucleotides; and

(ii) a ligase;

to produce a reaction mix comprising covalently closed circular molecules;

(c) treating at least some of the reaction mix of step (b) with an exonuclease to terminate the ligation and degrade any nucleic acid that is not a covalently closed circular molecule; and

(d) after step (c), quantifying the amount of covalently closed circular molecules produced in step (b).

2. The method of claim 1 , wherein the first and second conjugates bind to the target analyte with a low affinity.

3. The method of claim 1 , wherein the quantifying step (d) is done by quantitative PCR, digital PCR, by hybridization to a microarray or by sequencing.

4. The method of claim 3 , wherein the primers used for the quantitative PCR target the ligation junctions in the covalently closed circular molecules of (d).

5. The method of claim 1 , wherein step (d) comprises amplifying the covalently closed circular molecules by rolling circle amplification (RCA) to produce RCA products.

6. The method of claim 5 , wherein the method comprises counting the RCA products.

7. The method of claim 1 , wherein the reactions of steps (a)-(c) are done in the same vessel.

8. The method of claim 7 , wherein step (b) comprises adding the set of probes and ligase to the vessel comprising the product of step (a), and step (c) comprises adding one or more exonucleases to the vessel comprising the ligation product of step (b).

9. The method of claim 1 , wherein:

(i) the sample comprises a plurality of target analytes,

(ii) step (a) comprises incubating the sample with multiple pairs of said first and second conjugates, wherein each pair of conjugates binds to a different target analyte; and

(iii) step (d) comprises quantifying the number of covalently closed circular molecules corresponding to each target analyte.

10. The method of claim 1 , wherein the target analyte is a protein.

11. The method of claim 1 , wherein:

at least two members of the set of probes of step (b)(i) each have a molecular index; and

step (d) is done by i. sequencing the covalently closed circular molecules and then ii counting the number of covalently closed circular molecules using the index sequence.

12. The method of claim 1 , wherein the target analyte is a cytokine.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2020
From: PERSSON, HENRIK H.J.; JALILI, ROXANA; HORECKA, JOSEPH L.; DAVIS, RONALD W.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 051648/0147 →
Continuity (2)
Provisional Application 62465320 · Mar 1, 2017
Related Publication 20190360025A1 · Nov 28, 2019
Cited By (41)
US 12,195,790 US 12,203,134 US 12,209,280 US 12,223,751 US 12,228,544 US 12,241,060 US 12,241,890 US 12,249,085 US 12,265,079 US 12,270,077 US 12,275,988 US 12,281,357 US 12,286,673 US 12,287,264 US 12,297,486 US 12,344,892 US 12,365,935 US 12,365,942 US 12,371,688 US 12,378,607 US 12,385,083 US 12,399,123 US 12,404,544 US 12,405,264 US 12,416,603 US 12,435,363 US 12,442,045 US 12,497,654 US 12,508,590 US 12,529,094 US 12,545,949 US 12,553,805 US 12,553,898 US 12,566,113 US 12,566,114 US 12,571,029 US 12,624,475 US 12,637,706 US 12,668,835 US 12,692,492 US 12,704,508